Clinical Overview of Combination Therapy with Sitagliptin and Metformin
|
|
- Henry McDowell
- 6 years ago
- Views:
Transcription
1 Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1
2 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy (PN021, 023, A201) Complexities of getting patients to goal: a rationale for earlier combination therapy Mechanism of action of the co-administration of sitagliptin plus metformin Clinical data overview of combination therapy with sitagliptin and metformin 8
3 Major Pathophysiologic Defects in Type 2 Diabetes Islet-Cell Dysfunction Glucagon (α cell) Pancreas Hepatic glucose output Liver Insulin (β cell) Hyperglycaemia Insulin resistance Glucose uptake Muscle Adipose tissue Kahn CR, Saltiel AR. In: Kahn CR et al, eds. Joslin s Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins; 2005:
4 Mechanism of Action of Sitagliptin GI tract Ingestion of food Release of active incretins GLP-1 & GIP JANUVIA (DPP-4 inhibitor) Inactive GLP-1 X DPP-4 enzyme Inactive GIP Pancreas Beta cells Alpha cells Glucosedependent Insulin (GLP-1and GIP) Glucose dependent Glucagon (GLP-1) Glucose uptake by peripheral tissue Hepatic glucose production Blood glucose in fasting and postprandial states Incretin hormones GLP-1 and GIP are released by the intestine throughout the day, and their levels in response to a meal. Concentrations of the active intact hormones are increased by JANUVIA (sitagliptin phosphate), thereby increasing and prolonging the actions of these hormones. GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide.
5 Sitagliptin - Overview F F NH 2 O F N N N N CF 3 Provides potent and highly selective inhibition of the DPP-4 enzyme Fully reversible and competitive inhibitor DPP-4 inhibitor in development for the treatment of patients with type 2 diabetes, approved by the FDA on October , and approved in EU on March Approved in Korea on September
6 Pharmacokinetics of Sitagliptin Supports Once-Daily Dosing With once-daily administration, trough (at 24 hrs) DPP-4 inhibition is ~ 80% > 80% inhibition provides full enhancement of active incretin levels No effect of food on pharmacokinetics Well absorbed following oral dosing T max app 2 hours, t 1/2 app 12.4 hours at 100 mg dose Low protein binding, app 38% Primarily renal excretion as parent drug Approximately 80% of a dose recovered as intact drug in urine No clinically important drug-drug interactions No meaningful P450 system inhibition or activation
7 Single-Dose OGTT Study One Dose of Sitagliptin Inhibited Plasma DPP-4 Activity OGTT Inhibition of plasma DPP-4 activity from baseline (%) Hours post-dose Sitagliptin 25 mg (n=56) Sitagliptin 200 mg (n=56) Placebo (n=56) Trough DPP-4 inhibition ~80% ~50% OGTT=oral glucose tolerance test; AUC=area under the curve Herman et al. J Clin Endocrinol Metab, November 2006, 91(11): PN005
8 A Single Dose of Sitagliptin Increased Active GLP-1 and GIP Over 24 Hours Crossover study in patients with T2DM Placebo Active GLP-1 Active GIP Sitagliptin 25 mg 40 OGTT 2 hrs (n=55) OGTT 24 hrs (n=19) 90 OGTT 2 hrs (n=55) OGTT 24 hrs (n=19) Sitagliptin 200 mg GLP-1 (pg/ml) fold increase in active GLP-1 p< vs placebo GIP (pg/ml) fold increase in active GIP p< vs placebo Hours Postdose Hours Postdose Herman et al. J Clin Endocrinol Metab, November 2006, 91(11): PN005
9 A Single Dose of Sitagliptin Increased Insulin, Decreased Glucagon, and Reduced Glycemic Excursion After a glucose Load 40 Insulin Crossover Study in Patients with T2DM Placebo mciu/ml Drug Glucose Dose load 22% Sitagliptin 25 mg Sitagliptin 200 mg Glucose pg/ml p<0.05 for both dose comparisons to placebo for AUC Glucagon p<0.05 for both dose comparisons to placebo for AUC ~12% Drug Dose Glucose load Time (hours) ~26% p<0.001 for both dose comparisons to placebo for AUC Time (hours) Herman et al. J Clin Endocrinol Metab, November 2006, 91(11): PN005
10 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy (PN021, PN023, A201, and PN040) Complexities of getting patients to goal: a rationale for earlier combination therapy Mechanism of action of the co-administration of sitagliptin plus metformin Clinical data overview of combination therapy with sitagliptin and metformin 8
11 Sitagliptin Consistently and Significantly Lowers A1C with Once-Daily Dosing in Monotherapy Δchange vs placebo* 8.4 = 18-week Study -0.6% (p<0.001) week Study -0.79% (p<0.001) 8.4 Japanese Study -1.05% (p<0.001) A1C (%) 7.6 A1C (%) 7.6 A1C (%) Placebo (n=74) Sitagliptin 100 mg (n=168) 7.2 Placebo (n=244) Sitagliptin 100 mg (n=229) 6.8 Placebo (n=75) Sitagliptin 100 mg (n=75) Time (weeks) Time (weeks) Time (weeks) *between group difference in LS means Raz I et al. Diabetologia 2006;49: ; PN023; Aschner P et al. Diabetes Care 2006;29: ; PN021; Nonaka K et al; A201. Abstracts presented at: ADA
12 Sitagliptin Provides Significant and Progressively Greater Reductions in A1C with Progressively Higher Baseline A1C Inclusion Criteria: 7% 10% 18-week Study 24-week Study Baseline A 1c (%) <8% 8 9% >9% <8% 8 9% >9% Reduction in A 1c (%) Mean (%) N=96 N= N= Reduction in A 1c (%) N= N=62 N= N=37 N= Reductions are placebo-subtracted Raz I et al. Diabetologia 2006;49: ; PN023; Aschner P et al. Diabetes Care 2006;29: ; PN021; Nonaka K et al; A201. Abstracts presented at: ADA 2006
13 Sitagliptin Once Daily Significantly Improves Both Fasting and Post-meal Glucose In Monotherapy Fasting Glucose Post-meal Glucose 189 Δ FPG* = 17.1 mg/dl (p<0.001) 288 Δ in 2-hr PPG* = 46.7 mg/dl (p<0.001) 180 Plasma Glucose mg/dl Placebo (n=247) Sitagliptin 100 mg (n=234) Plasma Glucose mg/dl Baseline 24 weeks Placebo (N=204) Baseline 24 weeks Sitagliptin (n=201) Time (weeks) Time (minutes) * LS mean difference from placebo after 24 weeks Aschner P et al, PN021. Abstract presented at: American Diabetes Association; June 10, 2006; Washington, DC
14 Sitagliptin Improved Markers of Beta-Cell Function In 24-Week Monotherapy Study 0.55 Proinsulin/insulin ratio 80 HOMA-β 75 Ratio (pmol/l / pmol/l) p< 0.001* p< 0.001* Placebo Sitagliptin 100 mg 30 Placebo Sitagliptin 100 mg from baseline vs pbo = (95% CI , ) Hatched = Baseline Solid = Week 24 from baseline vs pbo = 13.2 (95% CI 3.9, 21.9) *P value for change from baseline compared to placebo Raz I et al. Diabetologia 2006;49: ; PN023; Aschner P et al. Diabetes Care 2006;29: ; PN021; Nonaka K et al; A201. Abstracts presented at: ADA 2006
15 Sitagliptin Monotherapy in Asian Patients (PN040) A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Sitagliptin Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
16 Study Design Patients with T2DM 18 years of age Not on AHA A1C 7.5% and 11% On AHA A1C 7% and 10% A1C 7.5 and 11% FPG 130 mg/dl and 280 mg/dl Single-Blind Placebo R Sitagliptin 100 mg Pbo Screening Period Diet/Exercise Run-in Period Single- Blind Placebo Run-in Double-Blind Treatment Period Visit 1 Screening Wk 9 Visit 2 Run-in Start Wk 8 Visit 3 Wk 5 Visit 4 Wk 2 Start SB Visit 5 Day 1 Randomization Visit 6 Wk 6 Visit 7 Wk 12 Visit 8 Wk 18 AHA = antihyperglycemic agent; FPG = fasting plasma glucose; R = randomization; T2DM = type 2 diabetes mellitus.
17 Baseline Glycemic and Disease Characteristics Balanced Between Groups Characteristic Sitagliptin (n=352) Placebo (n=178) Age (yrs) BMI (mean, kg/m2 ) A1C (%) FPG (mg/dl) Fasting insulin (μiu/ml ) Duration of Diabetes Mellitus ( yrs) HOMA Beta (%) 50.9 ± ± ± ± ± ± ± ± ± ± ± ±
18 Change from Baseline in HbA1c Full-Analysis-Set Population 0.4 LS Mean Change from Baseline % Sitagliptin 100 mg Week Placebo
19 Change from Baseline Per Country Country Group Placebo Subtracted % A1c change Placebo Subtracted mg/dl FPG Placebo Subtracted mg/dl PPG India Sita (n=119) Plbo (n=59) China Sita (n=158) Plbo (n=79) Korea Sita (n=62) Plbo (n=31)
20 HbA1c Reduction in Korean Diabetes Patients 0.8 Placebo 0.6 Sitagliptin 0.4 Mean change of A1C from baseline(%) Sitagliptin vs. placebo = -1.37% wks 6wks 12wks 18wks Group Sita (n=62) Plbo (n=31) Placebo Subtracted mg/dl FPG Placebo Subtracted mg/dl PPG
21 Summary (PN040: Sitagliptin Monotherapy in Asian patients) Sitagliptin demonstrated strong glycemic efficacy compared to placebo, as measured by HbA1c, FPG and PPG Sitagliptin was overall well tolerated No hypoglycemia For adverse experiences within GI system organ class, a higher incidence was observed with Sitagliptin
22 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy (PN021, 023, A201) Complexities of getting patients to goal: a rationale for earlier combination therapy Mechanism of action of the co-administration of sitagliptin plus metformin Clinical data overview of combination therapy with sitagliptin and metformin 8
23 ADA and IDF Guidelines: Treatment Goals for HbA 1c, FPG, and PPG Parameter Normal Level ADA Goal IDF Goal FPG, mg/dl (mmol/l) <110 (<6.1) ( ) <100 (<5.5) PPG, mg/dl (mmol/l) <140 (<7.8) <180 (<10.0) <140 (<7.8) HbA 1c 4% 6% <7%* <6.5% *Reference to a nondiabetic range of 4.0% to 6.0% using a DCCT-based assay. ADA=American Diabetes Association; IDF=International Diabetes Federation. American Diabetes Association. Diabetes Care. 2007;30(suppl 1):S4 S41; International Diabetes Federation. 2007:1 32. Buse JB et al. In Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders, 2003:
24 Societies Recommend Earlier Intervention to Help Attain Glycaemic Control 2006 Consensus statement from the ADA and EASD Our consensus is that an HbA 1c of 7 should serve as a call to action to initiate or change therapy If lifestyle intervention and maximal tolerated dose of metformin fail to achieve or sustain glycaemic goals, another medication should be added within 2 3 months of the initiation of therapy or at any time when HbA 1c goal is not achieved 2005 Global Guideline by IDF Begin with metformin unless evidence or risk of renal impairment, titrating the dose over early weeks to minimise discontinuation due to gastro-intestinal intolerance Step up doses, and add other glucose-lowering drugs, at frequent intervals until blood glucose control is at target levels EASD=European Association for the Study of Diabetes. Nathan DM et al. Diabetologia. 2006;49: ; International Diabetes Federation. 2005:
25 HbA 1c Levels Above ADA/EASD Target Goals Have Not Triggered Timely Therapy Modifications a 10 9 Metformin monotherapy (n=513 episodes) Sulfonylurea monotherapy (n=3394 episodes) 35 b 27 b months months HbA 1c, % ADA goal EASD goal 6 0 First HbA 1c on Treatment Best HbA 1c on Treatment Last HbA 1c before Switch or Addition c a US Physicians; b Mean number of months that elapsed until a new or additional treatment was started. c Monotherapy switched to another agent or additional agent added. Brown JB et al. Diabetes Care. 2004;27: ; American Diabetes Association. Diabetes Care. ADA=American Diabetes Association. 2007;30(suppl 1):S4 S41; Nathan DM et al. Diabetologia Aug;49(8): EASD=European Association for the Study of Diabetes. 11
26 Traditional Type 2 Diabetes Management: A Treat-to-Fail Approach Published Conceptual Approach Mean HbA 1c of patients Diet and exercise OAD monotherapy OAD up-titration OAD combination OAD plus basal insulin OAD plus multiple daily insulin injections 10 HbA 1c, % Time Duration of Diabetes OAD=oral anti-hyperglycaemic drug. Adapted from Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol. 2000;7(10): Del Prato S et al. Int J Clin Pract. 2005;59:
27 Less than 50% of Adults With Type 2 Diabetes Have Achieved HbA 1c Goals 60 US Population NHANES III ( ) (n=1204) NHANES (n=370) Adults, % HbA 1c level <7% Blood pressure <130/80 mmhg Total cholesterol <200 mg/dl Achieved all 3 treatment goals CV Risk Factors NHANES=National Health and Nutrition Examination Survey of a US population. Adapted from Saydah SH et al. JAMA. 2004;291:
28 UKPDS: Improving HbA 1c Control Reduced Diabetes-Related Complications EVERY 1% reduction in HbA 1c Relative Risk N=3642 Diabetesrelated deaths REDUCED RISK (P<0.0001) 21% 1% Myocardial infarctions Microvascular complications 14% 37% Amputations or deaths from peripheral vascular disorders 43% UKPDF=United Kingdom Prospective Diabetes Study. Data adjusted for age, sex, and ethnic group, expressed for white men aged years at diagnosis and with mean duration of diabetes of 10 years. Stratton IM et al. UKPDS 35. BMJ 2000;321:
29 Major Targeted Sites of Oral Drug Classes Liver Pancreas Impaired insulin secretion Sulfonylureas Meglitinides DPP-4 inhibitors Muscle and fat Hepatic glucose overproduction Biguanides TZDs DPP-4 inhibitors Glucose level Gut Glucose absorption Insulin resistance TZDs Biguanides α-glucosidase inhibitors Biguanides DPP-4=dipeptidyl peptidase 4; TZDs=thiazolidinediones. Buse JB et al. In: Williams Textbook of Endocrinology. 10th ed. Philadelphia: WB Saunders; 2003: ; DeFronzo RA. Ann Intern Med. 1999;131: ; Inzucchi SE. JAMA 2002;287: ; Porte D et al. Clin Invest Med. 1995;18:
30 Mechanisms of Action of Major Oral Monotherapies Are Unable to Address the 3 Core Defects in Type 2 Diabetes Oral Monotherapies SUs Meglitinides TZDs Metformin α-glucosidase Inhibitors DPP-4 Inhibitors Mechanisms of Action Improves insulin secretion Improves insulin resistance Lowers hepatic glucose production SUs=sulfonylureas; TZD=thiazolidinediones; DPP-4=dipeptidyl peptidase 4. Inzucchi SE. JAMA 2002;287: ; Gallwitz B. Minerva Endocrinol. 2006;31: ; Nathan DM et al. Diabetologia. 2006;49:
31 Earlier Use of Combination Therapy May Improve Treating to Target Compared With Conventional Therapy Diet and exercise Published Conceptual Approach OAD monotherapy OAD up-titration OAD combination OAD plus basal insulin OAD plus multiple daily insulin injections 10 HbA 1c, % Mean HbA 1c of patients Time Duration of Diabetes OAD=oral anti-hyperglycaemic drug. Adapted from Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol. 2000;7(10): Del Prato S et al. Int J Clin Pract. 2005;59:
32 Summary Complexities of Getting Patients to Goal: A Rationale for Earlier Combination Therapy Percentage of patients with type 2 diabetes getting to glycaemic goal is far from optimal Current conventional treatment paradigm has been characterised by treatment to failure rather than treatment to success Physicians see adverse events and adherence as the main barriers to earlier use of current combination therapy regimens Revised/proactive treatment paradigm for type 2 diabetes, involving earlier use of combination therapy, is urgently needed to be more effective in reaching and maintaining HbA 1c goals Saydah SH et al. JAMA. 2004;291: ; Brown JB et al. Diabetes Care. 2004;27: ; Del Prato S et al. Int J Clin Pract. 2005;59: ; Campbell IW. Br J Cardiol. 2000;7: ; Grant RW, et al. Diabetes Care. 2003;26: ; Dailey G et al. Clin Ther. 2001;23:
33 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy (PN021, 023, A201) Complexities of getting patients to goal: a rationale for earlier combination therapy Mechanism of action of the co-administration of sitagliptin plus metformin Clinical data overview of combination therapy with sitagliptin and metformin (PN024) 8
34 The Combination of Sitagliptin and Metformin Addresses the 3 Core Defects of Type 2 Diabetes in a Complementary Manner Sitagliptin improves markers of β-cell function and increases insulin synthesis and release β-cell Dysfunction Insulin Resistance Metformin acts as an insulin sensitiser (liver>muscle/fat) Sitagliptin indirectly reduces HGO through suppression of glucagon from α cells Hepatic Glucose Overproduction Metformin significantly decreases HGO by directly targeting the liver to decrease gluconeogenesis and glycogenolysis HGO=hepatic glucose overproduction. Aschner P et al. Diabetes Care. 2006;29: ; Abbasi F et al. Diabetes Care. 1998;21: ; Inzucchi SE. JAMA 2002;287: ; Kirpichnikov D et al. Ann Intern Med. 2002;137:25 33; Zhou G et al. J Clin Invest. 2001;108:
35 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy (PN021, 023, A201) Complexities of getting patients to goal: a rationale for earlier combination therapy Mechanism of action of the co-administration of sitagliptin plus metformin Clinical data overview of combination therapy with sitagliptin and metformin (PN024) 8
36 HbA 1c With Sitagliptin or Glipizide as Add-on Combination With Metformin: Comparable Efficacy HbA 1c, % ±SE LSM change from baseline (for both groups): 0.7% Sulfonylurea a + metformin (n=411) Sitagliptin b + metformin (n=382) Achieved primary hypothesis of noninferiority to sulfonylurea Weeks Adapted from Nauck MA, Meininger G, Sheng D, et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9: with permission from Blackwell Publishing Ltd., Boston, MA. a Specifically glipizide 20 mg/day; b Sitagliptin 100 mg/day with metformin ( 1500 mg/day). Per-protocol population; LSM=least squares mean. 27 SE=standard error.
37 Greater Reductions in HbA 1c Associated With Higher Baseline HbA 1c 52-Week Post Hoc Analysis Baseline HbA 1c Category Mean Change From Baseline in HbA 1c, % <7% 7 to <8% 8 to <9% 9% n=117 n=112 n=179 n=167 n=82 n=82 n=33 n= Sulfonylurea a plus metformin Sitagliptin b plus metformin Adapted from Nauck MA, Meininger G, Sheng D, et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9: with permission from Blackwell Publishing Ltd., Boston, MA. a Specifically glipizide 20 mg/day. b Sitagliptin 100 mg/day with metformin ( 1500 mg/day); Per-protocol population. Add-on sitagliptin with metformin vs sulfonylurea with metformin study. 28
38 Sitagliptin With Metformin Provided Weight Reduction (vs Weight Gain) and a Much Lower Incidence of Hypoglycaemia Least squares mean change over time c Hypoglycaemia c Body Weight, kg ± SE Sulfonylurea a plus metformin (n=416) Sitagliptin b plus metformin (n=389) Δ between groups = 2.5 kg Weeks P<0.001 Adapted from Nauck MA, Meininger G, Sheng D, et al, for the Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9: with permission from Blackwell Publishing Ltd., Boston, MA. Patients With 1 Episode, % Sulfonylurea a plus metformin (n=584) Sitagliptin b plus metformin (n=588) 32% Week 52 P< % a Specifically glipizide 20 mg/day; b Sitagliptin (100 mg/day) with metformin ( 1500 mg/day); c All-patients-as-treated population. Least squares mean between-group difference at week 52 (95% CI): change in body weight = 2.5 kg [ 3.1, 2.0] (P<0.001); Least squares mean change from baseline at week 52: glipizide: +1.1 kg; sitagliptin: 1.5 kg (P<0.001). Add-on sitagliptin with metformin vs sulfonylurea with metformin study. 29
39 Summary: Sitagliptin or Glipizide as Add-on Combination With Metformin Efficacy profile Comparable efficacy in lowering HbA 1c Both provided greater HbA 1c reductions in patients with the highest baseline HbA 1c Safety profile Both were generally well tolerated Adverse event profiles (ie, serious and GI-related adverse events, those leading to discontinuation) were similar, with the exception of hypoglycaemia Significantly lower incidence of hypoglycaemic episodes associated with sitagliptin with metformin Body weight significantly decreased for sitagliptin with metformin, but increased for glipizide with metformin Nauck MA et al. Diabetes Obes Metab. 2007;9:
40 Summary Insulin resistance, β-cell dysfunction, and elevated hepatic glucose production are the 3 core pathophysiologies of type 2 diabetes Incretins positively affect glucose homeostasis by physiologically helping to regulate Insulin secretion from β cells in a glucose-dependent manner Glucagon secretion in a glucose-dependent manner Getting patients to goal may be enhanced by targeting all 3 core defects and hyperglycaemia in the fasting and post-prandial states Del Prato S, Marchetti P. Horm Metab Res. 2004;36: ; Porte D Jr, Kahn SE. Clin Invest Med. 1995;18: ; Drucker DJ. Diabetes Care. 2003;26: ; Nauck MA et al. Diabetologia. 1993;36: ; Monnier L et al. Diabetes Care. 2003;26: ; American Diabetes Association. Diabetes Care. 2007;30(Suppl 1):S4 S41; International Diabetes Federation. 2008:
41 Summary (Continued) Sitagliptin and metformin have complementary mechanisms of action that address all 3 core defects of type 2 diabetes Sitagliptin as add-on combination with metformin provided HbA1c reductions comparable to adding an SU With less hypoglycemia With weight loss Nauck MA et al. Diabetes Obes Metab. 2007;9: ;; Goldstein BJ et al. Diabetes Care. 2007;30: ; Hermansen K et al. Diabetes Obes Metab. 2007;9:
42 Thank You!
Sitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationla prise en charge du diabète de
N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationEfficacy and Safety of Sitagliptin in Various Clinical Settings of T2DM
Efficacy and Safety of Sitagliptin in arious Clinical Settings of T2DM Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Department of Internal Medicine Seoul National University College
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationMetabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D
2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDOI: /jemds/2014/2044 ORIGINAL ARTICLE
AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationCurrent Controversies in Diabetes Control
Current Controversies in Diabetes Control Dara P. Schuster, MD, FACE ADA, AACE/ACE, and ACP Guidelines: Treatment Goals for A1C, FPG, and PPG Parameter Normal 1,2 Level ADA 3 Goal AACE/ACE 2 Goal ACP 4
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationIncretin Hormones: Evolving Treatment Strategies For Type 2 Diabetes
WHAT EVERY PRACTITIONER SHOULD KNOW ABOUT Incretin Hormones: Evolving Treatment Strategies For Type 2 Diabetes Education Partner: What Every Practitioner Should Know About Incretin Hormones: Evolving Treatment
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationEffective and Safe Management of Patients With Type 2 Diabetes and Chronic Kidney Disease Using Sitagliptin
2013 춘계당뇨병학회 Effective and Safe Management of Patients With Type 2 Diabetes and Chronic Kidney Disease Using Sitagliptin Eun Seok Kang Yonsei University College of Medicine Severance Hospital Diabetes
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationPRODUCT INFORMATION JANUVIA. (sitagliptin phosphate monohydrate)
0431-AUS-2012-004879 1 PRODUCT INFORMATION JANUVIA (sitagliptin phosphate monohydrate) DESCRIPTION JANUVIA (sitagliptin phosphate monohydrate) is an orally-active inhibitor of the dipeptidyl peptidase
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationCombination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
REVIEW Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential Nasser Mikhail Endocrinology Division, Olive View-UCLA Medical
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationBarriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia. KM Pantalone Endocrinology
Barriers to Achieving A1C Targets: Clinical Inertia and Hypoglycemia KM Pantalone Endocrinology Disclosures Speaker Bureau AstraZeneca, Merck, Novo Nordisk, Sanofi Consultant Novo Nordisk, Eli Lilly, Merck
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationMechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Adv Ther (2013) 30(2):81 101. DOI 10.1007/s12325-013-0009-4 REVIEW Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes Michael Horowitz Christopher K. Rayner Karen L.
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationSitagliptin. Agreed by Clinical Priorities Group
New Medicine Report Document Status Sitagliptin Agreed by Clinical Priorities Group Traffic Light Decision Blue- Primary Care Prescriber s Rating Offers an advantage - The product has some value but does
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationCANA DAPA EMPA. Change in Baseline Body Weight (kg) *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg, EMPA=10 or 25 mg.
CANA DAPA EMPA Change in Baseline Body Weight (kg) 2 1 0-1 -2-3 -4-5 PBO SGLT2 inhibitor (low dose)* SGLT2 inhibitor (high dose)* *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg,
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationInitial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
The journal of interventions in clinical practice www.drugsincontext.com CLINICAL COMMENTARY FULL TEXT ARTICLE Initial combination therapy for patients with type 2 diabetes mellitus: considerations for
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationResults of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 June 13, 2005 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-5203-8105 Results of Phase II Studies of Sitagliptin (MK-0431
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationUpdate on DPP-4 Inhibition in T2DM: Implications from Recent and Ongoing Trials
Update on DPP-4 Inhibition in T2DM: Implications from Recent and Ongoing Trials Richard Pratley, M.D. Samuel Crockett Chair in Diabetes Research Director, Florida Hospital Diabetes Institute Senior Investigator,
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationClinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More information